ProfileGDS5678 / 1445083_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 5% 5% 5% 5% 5% 4% 6% 5% 4% 5% 5% 4% 4% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.069125
GSM967853U87-EV human glioblastoma xenograft - Control 22.051435
GSM967854U87-EV human glioblastoma xenograft - Control 32.052715
GSM967855U87-EV human glioblastoma xenograft - Control 42.024265
GSM967856U87-EV human glioblastoma xenograft - Control 52.006825
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.081664
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.128636
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.033655
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.022174
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.045835
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.035115
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.002014
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.040764
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.041255